About Epeius Biotechnologies Corporation

The visionary business builders of Epeius Biotechnologies Corporation share an abiding passion for the pursuit of excellence in science focused sharply on the development of superior medicines for cancer. Founded in 2000, and incubated at The University of Southern California School of Medicine, Epeius Biotech emerged in 2002 as a free standing company with an enviable IP portfolio, a high-value tumor-targeting platform and lead product that has been validated in the crucible of clinical medicine, and revenues beginning in 2006. Epeius Biotechnologies is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems and high-value oncology products. Credited with innovations ranging from gene discovery, therapeutic designer genes, pathotropic (disease-seeking) targeting, high-performance vector engineering, to advanced GMP & Bioprocess development, Epeius is an acknowledged leader in the field of genetic medicine with an impressive intellectual property estate. Rapid advances in clinical development have provided Epeius with a unique opportunity for early revenues from the exportation and sale of its lead product to the Philippines and reciprocating Southeast Asian countries, thus demonstrating the high-growth potential of an innovative biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product.